Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: December 8, 2016

Completion of rights issue and notice shortfall

News & Announcements 2016By PharmAust December 8, 2016

161208_COMPLETION OF RIGHTS ISSUE AND NOTICE OF SHORTFALL

Recent Articles

200921_PharmAust Awarded FightMND Grant for Phase I Trial
September 21, 2020
14 September, Shareholder Update
September 14, 2020
Elanco not to Exercise Agreed Option
September 9, 2020
Monepantel Anti-Covid-19 Activity Confirmed
September 9, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

Brad Turner @turnerMNDlab·

Exciting news about a world-first trial of monepantel for #MND #ALS in Australia. https://twitter.com/pharmaust/status/1307832264269598720

PharmAust@PharmAust

PharmAust receives grant from FightMND for monepantel phase one trial in motor neuron disease https://smallcaps.com.au/pharmaust-fightmnd-monepantel-phase-one-trial-motor-neuron-disease/ via @SmallCapsASX

Reply on Twitter 1307873727913193474 Retweet on Twitter 13078737279131934742 Like on Twitter 130787372791319347410 Twitter 1307873727913193474

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions